ArticleJournal of pharmaceutical policy and practice2026
A qualitative study to explore the perspectives of key stakeholders regarding pharmaceutical pictograms in Pakistan.
Article in Journal of pharmaceutical policy and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This qualitative study in Pakistan aims to gather perspectives from health regulators, pharmaceutical manufacturers, and healthcare professionals regarding the implementation of pharmaceutical pictograms. Methods: An exploratory qualitative study design was used to conduct this study across all provinces of Pakistan. The study adopted a constructivist approach to examine stakeholders' subjective interpretations and to ensure methodological transparency, Consolidated Criteria for Reporting Qualitative Research (COREQ) guidelines were used as reporting guidelines. The data were collected from three main groups through in-depth, face-to-face interviews. The study participants were recruited using a purposive convenience sampling technique. Data analysis was conducted using an inductive thematic analysis approach to draw conclusions aligned with the study objectives. Results: A total of 57 respondents participated in the study, including 13 doctors, 15 pharmacists, 15 health regulators, and 14 manufacturers. Analysis of the data yielded five themes and sixteen subthemes. The five key themes were extracted including the current status of pharmaceutical pictograms, the impact of pharmaceutical pictograms, the significance of pharmaceutical pictograms on patients and the healthcare system, and challenges in the implementation of pharmaceuticals. The majority of the respondents demonstrated a better understanding of the term 'pharmaceutical pictograms,' but awareness of standardised systems (USP and FIP) was limited. However, several implementation challenges were identified, including a lack of government recognition and policy support, insufficient training and knowledge among healthcare professionals, and financial or resource constraints. Stakeholders emphasised national policy, training, and awareness to integrate pharmaceutical pictograms. Conclusion: The key stakeholders strongly favoured the implementation of pharmaceutical pictograms, recognising their potential to enhance patient comprehension, adherence, and overall safety in Pakistan. However, their adoption is limited by insufficient awareness, policy support, and resources. Addressing these challenges through national policies, professional training, and awareness initiatives is essential for the successful adoption of pictograms in the healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.